Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • kgosche@partek.com
    Member
    • Aug 2016
    • 16

    #1

    Analyzing Cell-Free DNA Seq Data from Cancer Patients to find Actionable Variants

    Webinar:
    How to Analyze Cell-Free DNA Sequencing Data from Cancer Patients to Identify Clinically Actionable Variants

    In this webinar, whole exome sequencing data of tumor tissue and cell-free DNA derived from two cancer patients will be used to demonstrate how non-invasive liquid biopsies from the blood have the potential to aid in precision medicine. Using Partek® Flow® software, a powerful and easy-to-use bioinformatics tool, we will analyze raw sequence data from individuals with metastatic sarcoma and metastatic breast cancer to identify clinically actionable variants.

    You will learn how to:
    • Align and filter whole exome sequencing data
    • Detect variants from tumor and cell-free DNA
    • Perform annotation and filtering to prioritize variants

    Live Sessions Offered:
    • September 27, 2017 at 10am SGT (Singapore)
    • September 28, 2017 at 2pm GMT (London)
    • September 28, 2017 at 2pm EDT (Boston)

    REGISTER NOW

Latest Articles

Collapse

  • SEQadmin2
    Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
    by SEQadmin2



    CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

    Despite this, “CRISPR helped turn genome editing from a specialized technique into
    ...
    07-31-2026, 11:01 AM
  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, Today, 10:35 AM
0 responses
4 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 08-06-2026, 07:41 AM
0 responses
23 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 08-03-2026, 10:13 AM
0 responses
40 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-31-2026, 02:55 AM
0 responses
47 views
0 reactions
Last Post SEQadmin2  
Working...